Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
about
Targeting the hepatocyte growth factor-cMET axis in cancer therapyDiscovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapyAptamers: A promising chemical antibody for cancer therapyTargeting RTK Signaling Pathways in CancerTargeting angiogenesis in gynecologic cancersMET inhibitors for treatment of advanced hepatocellular carcinoma: A reviewResistance and escape from antiangiogenesis therapy: clinical implications and future strategiesStructural basis for agonism and antagonism of hepatocyte growth factorMolecular pathology of lung cancer: key to personalized medicine.Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinomaThe potential therapeutic applications and prognostic significance of metastasis-associated in colon cancer-1 (MACC1) in cancersSynergistic Anticancer Effect of Tocotrienol Combined with Chemotherapeutic Agents or Dietary Components: A ReviewRoles of c-Met and RON kinases in tumor progression and their potential as therapeutic targetsOrder and disorder in large multi-site docking proteins of the Gab family--implications for signalling complex formation and inhibitor design strategiesCardiovascular effects in rats following exposure to a receptor tyrosine kinase inhibitorMetastasis suppressor genes at the interface between the environment and tumor cell growthA human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinomaThe oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitorEfficiently prepared ephedrine alkaloids-free Ephedra Herb extract: a putative marker and antiproliferative effectsUveal melanoma: epidemiology, etiology, and treatment of primary disease.MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agentsConstitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607.The biological basis for modern treatment of chordoma.Olive phenolics as c-Met inhibitors: (-)-Oleocanthal attenuates cell proliferation, invasiveness, and tumor growth in breast cancer modelsBlood vessel endothelium-directed tumor cell streaming in breast tumors requires the HGF/C-Met signaling pathway.Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles.The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue.Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma3,3'-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutantsEngineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonists.Molecular sub-classification of renal epithelial tumors using meta-analysis of gene expression microarrays.GATA2 is epigenetically repressed in human and mouse lung tumors and is not requisite for survival of KRAS mutant lung cancer.In vitro and in vivo effects of suppressor of cytokine signalling 7 knockdown in breast cancer: the influence on cellular response to hepatocyte growth factor.High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in CancerThe Met oncogene and basal-like breast cancer: another culprit to watch out for?
P2860
Q24606259-4F03515A-4970-49A9-8D8D-F8A3DAE3A059Q24608143-CF5603DB-B207-449C-8A03-B3A1876930DEQ26741201-0816079E-681E-402C-918F-B6E13C5E6912Q26741450-29D80FAA-0445-4C4D-BDCF-CB3EB08F2F4AQ26766832-7AA20004-51F2-4A41-B5EF-558D830B6903Q26781278-E5EA0C5D-021C-4E30-BFCB-A8772F0CF0E8Q26824766-8F36B1A5-EEE0-40E9-9685-4CC0E77F90FCQ27014423-B40C0009-F375-4410-A68A-1D78990596F8Q27016629-F5A01226-FBBE-49D5-A93C-E7C5A16D0066Q27663368-2CEE5263-4FB4-4AA9-949B-78820D44B2C5Q27691299-7E2E355A-78BB-4353-849E-284DDA30D4CCQ27851979-13B85400-670D-45EC-9ACF-03FA46D90235Q28066094-8AB7CA14-4394-44EC-B117-1CD7EB83C1E1Q28074119-298DE424-020A-4D91-AAF0-B7F93A34884CQ28081193-A7F383CC-F822-4241-9EB7-DAD2377D220AQ28248627-7252A1B2-2647-48CC-B241-0EBD7F9CF381Q28276103-D6BFCA71-35D3-4CD3-A6AC-D4B88F12C270Q28394526-79A62E7A-BCEB-4DF0-8B2A-15A78442CA1AQ28487973-C3EC9617-4177-4204-B092-8B84E71B338CQ28821187-D2E193FC-E7CA-4FB9-9F5C-DAA55313A401Q28831165-F465CDBD-7F99-4D6C-AD03-721688BE432AQ30235934-63759038-EB5F-4A5F-BE7C-F0F0DDCBEEB8Q30502341-056585F7-4925-4D64-AF26-076C229329C4Q31062741-743F0897-9D52-4C37-B2B8-9A821BE62A0EQ33274086-8CDDC9E1-15CC-4478-A1E5-42251C1C7813Q33645135-4DF7E794-17D6-4977-AF90-4BD44495E524Q33665092-65793B61-717A-4482-9E9B-051FEA5A7A76Q33737789-83E78DE5-4090-4EB9-B92E-CD3567069C66Q33769429-C91C082E-4690-4EF9-81F2-58D107699717Q33830522-BBDD04F9-234A-475F-892F-6ACB6C823121Q33901521-EEC3EEC9-4ECA-42E4-9614-5A225769E256Q33918113-61E24A55-7E46-43E2-BFB3-26EEFA7574B6Q33937876-25C30CB5-B9AA-40FB-A52B-8220CED5D066Q33970874-53E6D989-E2D2-4CC2-9B58-D5D899BF529CQ33982903-E8541F7B-E1AC-46E3-BF8F-1DC521FFC08BQ34044005-479519A4-8A47-48BC-849A-B2140B5D0A60Q34064613-391C7A46-2944-4B56-A968-299792689AA8Q34128962-20B59739-9868-4364-9A86-3BF02718268EQ34141913-26F56377-A622-4D9A-AAFF-49A07DCD084DQ34173500-1B5E171B-E750-4D46-9720-8486D38B658D
P2860
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
@en
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
@nl
type
label
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
@en
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
@nl
prefLabel
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
@en
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
@nl
P2093
P1476
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
@en
P2093
George F Vande Woude
Joseph Paul Eder
Patricia M LoRusso
Scott A Boerner
P304
P356
10.1158/1078-0432.CCR-08-1306
P407
P577
2009-03-24T00:00:00Z